Acute effects of sildenafil on uroflowmetric parameters in erectile dysfunction patients with and without lower urinary tract symptoms

Journal of Andrology

Volumn 33, Issue 6, 2012, Pages 1165-1168

  Öztürk, Metin I ^a   Koca, Orhan ^a   Sertkaya, Zülfü ^a   Keleş, Muzaffer O ^a   Kaya, Cevdet ^a   Karaman, Muhammet I ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

Acute urinary retention; BPH; Uroflowmetry

Indexed keywords

SILDENAFIL;

ADULT; ARTICLE; DRUG EFFECT; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; URINE FLOW RATE; UROFLOWMETRY;

ADULT; ERECTILE DYSFUNCTION; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROSTATIC HYPERPLASIA; PURINES; SULFONES; URINATION; URODYNAMICS;

EID: 84874400517     PISSN: 01963635     EISSN: 19394640     Source Type: Journal    
DOI: 10.2164/jandrol.111.015776     Document Type: Article

References (21)

1. Corbin JD, Francis SH, Webb DJ. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology. 2002;60suppl 2:4-11.
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, Mckinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61.
3. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, Gacci M, Vignozzi L, Vannelli GB, Carini M, Forti G, Maggi M. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology. 2007;148:1019-1029.
4. Güler C, Tüzel E, Doǧantekin E, Kiziltepe G. Does sildenafil affect uroflowmetry values in men with lower urinary tract symptoms suggestive of benign prostatic enlargement? Urol Int. 2008;80: 181-185.
5. Guven EO, Balbay MD, Mete K, Serefoglu EC. Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia. Int Urol Nephrol. 2009;41:287-292.
6. Haaga JR, Exner A, Fei B, Seftel A. Semiquantitative imaging measurement of baseline and vasomodulated normal prostatic blood flow using sildenafil. Int J Impot Res. 2007;19:110-113.
7. Kedia GT, Uckert S, Kedia M, Kuczyk MA. Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology. 2009;73:1397-1401.
8. Khastgir J, Khan A, Speakman M. Acute urinary retention: medical management and the identification of risk factors for prevention. Nat Clin Pract Urol. 2007;4:422-431.
9. Leungwattanakij S, Watanachote D, Noppakulsatit P, Petchpaibuol T, Choeypunt N, Tongbai T, Wanamkang T, Lojanapiwat B, Permpongkosol S, Tantiwong A, Pripatnanont C, Akarasakul D, Kongwiwatanakul S, Chotikawanich E. Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand. J Sex Med. 2010;7:3115-3126.
10. Mcvary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int. 2006a;97suppl 2: 23-28.
11. Mcvary KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006b;12(SUPPL):S122-S128.
12. Mcvary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007;177:1071-1077.
13. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53(suppl 1):5S-12S.
14. Parsons BA, Bright E, Shaban AM, Whitehouse A, Drake MJ. The role of invasive and non-invasive urodynamics in male voiding lower urinary tract symptoms. World J Urol. 2011;29:191-197.
15. Qiu Y, Kraft P, Craig EC, Liu X, Haynes-Johnson D. Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle. Urology. 2002;59:145-149.
16. Reynard JM, Peters TJ, Lim C, Abrams P. The value of multiple freeflow studies in men with lower urinary tract symptoms. Br J Urol. 1996;77:813-818.
17. Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion-Mboussa A, Viktrup L. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int. 2010;105:502-507.
18. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppo P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44:637-649.
19. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008;53: 1236-1244.
20. Tinel H, Stelte-Ludwig B, Hü tter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int. 2006;98:1259-1263.
21. Uckert S, Küthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol. 2001;166:2484-2490.